Cognitive testing provision for phase II RCT of THN391 for early Alzheimer’s Disease

A Phase IIb clinical trial for an Alzheimer's drug will use a remote cognitive testing system to track patients' mental abilities from their own homes. This matters because Alzheimer's disease trials typically require patients to travel repeatedly to clinics for cognitive assessments, which is burdensome and can limit who can participate. The PROTECT Cognitive Test System, part of a digital health platform, allows testing to happen remotely and at multiple time points, potentially making trials more efficient and inclusive. The system also handles data monitoring and safety monitoring for the trial. If this approach proves effective, it could change how pharmaceutical companies run clinical trials for Alzheimer's and other neurological conditions. Instead of relying solely on infrequent clinic visits, researchers could gather more frequent, real-world data on how a drug affects cognition. This might speed up drug development and reduce the logistical barriers that currently exclude many patients from participating in research. The immediate impact is on clinical trial infrastructure rather than on patients' daily lives, but better trials are a necessary step toward better treatments.